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Abstract
Background: Intranasal administration of high amount of allergen was shown to induce tolerance and
to reverse the allergic phenotype. However, mechanisms of tolerance induction via the mucosal route
are still unclear. Objectives: To characterize the therapeutic effects of intranasal application of
ovalbumin (OVA) in a mouse model of bronchial inflammation as well as the cellular and molecular
mechanisms leading to protection upon re-exposure to allergen. Methods: After induction of
bronchial inflammation, mice were treated intranasally with OVA and re-exposed to OVA aerosols
10 days later. Bronchoalveolar lavage fluid (BALF), T cell proliferation and cytokine secretion were
examined. The respective role of CD41CD251 and CD41CD252 T cells in the induction of tolerance
was analysed. Results: Intranasal treatment with OVA drastically reduced inflammatory
cell recruitment into BALF and bronchial hyperresponsiveness upon re-exposure to allergen. Both
OVA- specific-proliferation of T cells, Th1 and Th2 cytokine production from lung and bronchial lymph
nodes were inhibited. Transfer of CD41CD252 T cells, which strongly expressed membrane-bound
transforming growth factor b (mTGFb), from tolerized mice protected asthmatic recipient mice from
subsequent aerosol challenges. The presence of CD41CD251(Foxp31) T cells during the process of
tolerization was indispensable to CD41CD252 T cells to acquire regulatory properties. Whereas the
presence of IL-10 appeared dispensable in this model, the suppression of CD41CD252mTGFb1
T cells in transfer experiments significantly impaired the down-regulation of airways inflammation.
Conclusion: Nasal application of OVA in established asthma led to the induction of
CD41CD252mTGFb1 T cells with regulatory properties, able to confer protection upon allergen
re-exposure.
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Introduction
Although Th2 polarization cannot fully explain a complex
allergic condition such as asthma (1), allergen-specific
immunotherapy (SIT) in human was shown to derive the
allergen-specific Th2 immune response towards a Th1 re-
sponse (2–4) and in parallel to enhance a T regulatory cell
response based on activation of IL-10-producing CD4+CD25+
T cells (5–7). In addition, several studies demonstrated the
efficacy of SIT not only in improving asthma symptoms (8, 9)
but also in delaying the progression from allergic rhinitis to
asthma in children (10). Hence, induction of tolerance to al-
lergen appears as an efficient treatment strategy to establish
both an early prophylactic as well as a therapeutic control of
the specific mechanisms leading to allergic inflammation.
In naive animals, application of high-dose allergen on
the respiratory or nasal mucosa was able to hamper the
development of airway hyperresponsiveness (AHR) and/or
Th2-polarized responses (11–13). Two cell lineages were
considered key players in the induction of immune tolerance
to allergen: dendritic cells (DCs) and CD4+ T cells (14). In
prophylactic models, the development of respiratory toler-
ance was initiated by uptake of antigen in the lungs by im-
mature DC that continuously sampled foreign antigens in
the bronchial mucosa (15). As proposed in early studies,
after exposure to ovalbumin (OVA), immature pulmonary DC
migrate to the draining bronchial lymph nodes (BLN) where
they mature and initiate a phase of allergen-specific T-cell
activation, proliferation and expansion, followed by T-cell
depletion from lymphoid organs. A stable population of
T cells could survive but remained refractory to antigenic
re-exposure (anergy) (12, 14, 16).
Whereas nasal application of allergen or allergen-derived
peptides significantly improved established systemic hyper-
sensitivity to OVA or phospholipase A2 (16, 17), the possibility
of reducing bronchial inflammation in established asthma via
the nasal route is still debated (13, 18). Mechanisms of pro-
tection are yet incompletely understood although a role for
IL-10, transforming growth factor (TGF) b and CD25+ T cells
has been suggested (19–23). Furthermore, we have recently
shown that CD4+CD25+(Foxp3+) T-cell depletion fully abro-
gated tolerance induction via the intranasal route in an experi-
mental model of asthma (24). Therefore, to evaluate the
therapeutic potential of antigen SIT via the nasal route and to
better understand the mechanisms of induction of tolerance
to allergen, we further dissected our experimental mouse
model of asthma to OVA that displays full blown features of
reversible airway inflammation and provided conditions com-
patible with allergen seasonal exposure in human.
Methods
Induction of asthma and intranasal treatment
Six- to 8-week-old BALB/c mice (Harlan, Horst, The Nether-
lands) were sensitized twice at day 0 (D0) and D14 by intra-
peritoneal (i.p.) injections of 10 lg OVA (LPS <15 pg mg1;
Fluka, Buchs, Switzerland) adsorbed on 1 mg aluminum
hydroxide (Sigma Chemicals, St Louis, MO, USA). At D24,
D26 and D28, animals were exposed to a single aerosol of
OVA in PBS (0.25%) (Fig. 1 window). Aerosolization was gen-
erated by a nebulizer (De Vilbiss; Sunrise medical GmBH,
Malsch, Germany) for 20 min. At D38, 39 and 40 mice were
treated intranasally with OVA 0.5 mg, 1.0 mg or 1.5 mg [OVA
intranasal treatment (INT) group] or PBS (control group; PBS
Fig. 1. INT with OVA protects against cell recruitment into BALF upon OVA aerosol challenge. Total BALF cell number (A and D), relative
eosinophil count in % (B and E) and mononuclear cell subpopulations number (C and F) in BALF harvested after INT (D47) or after challenge
(D57), in animals treated intranasally with 0.5, 1.0 or 1.5 mg OVA versus PBS. *P < 0.05; **P < 0.01; ***P < 0.001. Window: model’s treatment
scheme; crosses indicate sacrifice.
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INT group) or human serum albumin (0.25%; CLS Behring,
Switzerland) when indicated (Fig. 2C and D), under light
anaesthesia with halotane (Halocarbon B.P.; Arovet A.G., Zol-
likon, Switzerland). Mice were finally challenged with 0.25%
OVA aerosol at D50, D52 and D54 and sacrificed at D57.
When indicated (Fig. 8), wild-type C57BL/10 and C57BL/10
IL10/ mice (B10.129P2(B6)-Il10tm1Cgn/J) (Charles River,
France) maintained in pathogen-free environment were
treated following the same protocol.
Bronchoalveolar lavage and AHR
Bronchoalveolar lavage was performed by injecting a total
of 3 ml PBS (6 3 500 ll) into the lung. Approximately 105
cells in 100 ll were centrifuged on glass plates (Cytospin;
Shandon scientific, Cheshire, U.K) and then stained with
DiffQuik according to the manufacturer’s recommendations
(Baxter Dade, Dudingen, Switzerland). A differential count
of 200 cells was performed using standard morphological
criteria. AHR was measured in conscious unrestrained mice
using barometric whole-body plethysmography (Buxco;
EMKA technologies, Paris, France). Respiratory pressure
curves were recorded in response to inhaled methacholine
(Sigma Chemicals).
Proliferation assay
Proliferation assays were done as previously described (16).
Briefly, 1 3 105 BLN cells or 5 3 105 splenocytes were stimu-
lated with or without 5 lg ml1 OVA for 4 days, and cell prolif-
eration was measured by 3H-thymidine incorporation.
Alternatively, CD4+-enriched T cells (using magnetic beads
from BD PharMingen, San Diego, CA, USA) from spleens of
DO11.10 mice were labelled with carboxyfluorescein succini-
midyl ester (CFSE) (Molecular probes, Invitrogen, Carlsbad,
CA, USA) (25). At D54, 3 3 106 KJ1-26+CD4+ T cells were
injected into the tail vein of asthmatic BALB/c mice following
previous protocols (26). Recipient mice were sacrificed at
Fig. 2. OVA INT protects against re-exposure to OVA aerosol for an extended period of time in an antigen-specific manner and limits bronchial
hyperresponsiveness and T-cell proliferation. (A) Eosinophil number in BALF after extension of interval between INT and challenge to 10, 18 or
32 days. *compared with PBS; #compared with 10 days. (B) Sensitized mice were challenged twice 30 and 60 days after INT, and eosinophils
were quantified in BALF 3 days after the last challenge. (C and D) Induction of tolerance is antigen specific: INTwas done either with PBS, 1.5 mg
OVA or 1.5 mg human serum albumin in OVA-sensitized mice. Eosinophil number (C) and eosinophil percentage (D) in BALF at D57. (E) At D56,
PenH was evaluated by whole-body plethysmography after stimulation with indicated methacholine concentrations. (F) Total lung EPO activity at
D47 and D57, expressed as optical density (OD). *compared with PBS; #compared with D47. (G) BLN and spleen cells proliferation in response
to 5 lg ml1 OVA. Data are expressed as stimulation indexes (SI). (H) CFSE-labelled-CD4+-enriched splenocytes from DO11.10 mice were
transferred in OVA-sensitized BALB/c mice intranasally treated with OVA (lower panel) or PBS as a control (upper panel). Mice were sacrificed at
D57 and single-cell suspension of BLN were labelled with surface antibodies against KJ1-26 (DO11.10 specific) (BD PharMingen). Samples were
analysed on a FACScalibur and fluorescence was determined using CellQuest software (BD Biosciences). Numbers indicate percentage of
cells undergoing more than one, one or no division. *P < 0.05; **P < 0.01; ***P < 0.001.
CD4+CD25mTGFb+ T cells transfer tolerance 19
D57 (3 days post-aerosol challenges). CFSE-labelled KJ1-26+
T-cell divisions were detected by flow cytometry.
Antibody isotypes
Serum IgE, IgG1 and IgG2a antibody response was determined
by ELISA as described (16, 27). Alternatively, IgE were mea-
sured by indirect ELISA. Briefly, plates coated with 2 lg ml1
rat anti-mouse IgE mAb (BD PharMingen) were incubated with
mouse serum (1:100) for 2 h at 37C, then with 500 ng ml1
biotinylated OVA and revealed with alkaline phosphatase.
Cell preparation and inflammatory markers measurement
Lungs were harvested, snap frozen in dry ice and kept
at 80C until use. Frozen lungs were homogenized in
a Dounce tissue grinder with 1 ml PBS containing protease
inhibitors (Complete, Roche Diagnostics GmbH, Basel,
Switzerland) and centrifuged for 4 min at 1640 3 g. Super-
natants of lung homogenates were collected for cytokines
measurements. In addition, cytokines were measured in
supernatants from BLN or lung cells cultured for 3 days
at 37C in 5% CO2. A total of 106 fresh cells from BLN or
3 3 106 fresh cells from the lungs were seeded in 48- (BLN)
or 24- (lung) wells plates with 125 lg ml1 OVA in DMEMc.
(DMEM (Gibco-BRL, Life technologies, AG, Basel, Switzerland)
supplemented with 50 mM beta-mercaptoethanol (Fluka,
Buchs, Switzerland), 2mM L-glutamine, 1mM sodium-pyruvate,
1mM HEPES, 100 IU/mL penicillin-streptomycin and 10%
FCS (Gibco-BRL)). Cytokines levels were determined by
ELISA according to the manufacturers’ recommendations
(BD PharMingen for IL-5 and IFNc; R&D Systems, Minneap-
olis, MN, USA, for IL-10, IL-4, IL-13 and TGFb). Eosinophil
peroxidase (EPO) activity was measured in lung homoge-
nates processed as described in ref. (28) and according to
Strath et al. (29).
Cell enrichment and transfer
Lungs from PBS INT or OVA INT mice were harvested at
D52; single-cell suspension were performed and thereafter
enriched in CD4+ T cells on magnetic beads according to
the manufacturer (BD Biosciences) (Fig. 7A). More than
90% CD4+ pure fractions were obtained. Where indicated,
CD25+ cells or CD25+mTGFb+ cells were positively selected
by magnetic cell sorting according to the manufacturer
(Miltenyi Biotech GmBH, Bergisch Gladbach, Germany).
Purity was typically >85%. A total of 1 3 106CD4+ or 5 3
105CD4+CD25+ or CD4+CD25 cells were re-suspended in
NaCl 0.9% and 100 ll were injected in the tail vein of OVA-
sensitized mice at D35. Recipient mice were challenged
with OVA aerosol 1, 3 and 5 days after cell transfer and
sacrificed 3 days later (D43).
Anti-CD25 mAb PC61 and CD25+ T cells depletion
Anti-mouse CD25 mAb PC61 (rat IgG1, kind gift from
Dr. A. Wilson; Ludwig Institute, Epalinges, Switzerland) was
purified from culture supernatant on protein G sepharose
column. Mice were treated i.p. with 1 mg PC61 at days 31,
38 and 45 (Fig. 7A). A single i.p. treatment with 1 mg PC61
yielded >80% CD4+CD25+ T cells depletion in PBMC and
spleen during 7 days (24).
Flow cytometry
IL-10 expression was monitored using the ‘MACS Mouse
IL-10 secretion assay kit’ (Miltenyi Biotech). According to
the manufacturer, single-cell suspensions from BLN or
lungs stimulated for 3 days with OVA (125 lg ml1) were
labelled with antibodies to IL-10, CD4 and CD45R/B220 (BD
PharMingen). IL-10-secreting cells were further labelled with
anti-PE magnetic microbeads and enriched over a MACS
separator system. Membrane-bound transforming growth
factor b (mTGFb) expression on BLN cells was performed
with an anti-TGFb mAb (IQ Products, Groningen, The
Netherlands). Samples were analysed on a FACScalibur
and fluorescence intensity was determined using Cell-
Quest software (both from BD Biosciences).
Statistical analysis
Results are expressed as mean 6 SD of four to six mice per
group. Each experiment was done at least three times. Sig-
nificance of differences between means was determined by
Student’s t-test using Prism 4.00 software for Windows
(GraphPad Software Inc., La Jolla, CA, USA).
Results
INT with OVA inhibits inflammatory cell recruitment into bron-
choalveolar lavage fluid (BALF) upon re-exposure to OVA.
To induce bronchial inflammation, mice were first sensitized
by two i.p. injections of OVA and a series of three OVA aero-
sols as described in Methods. At day 31, these mice dis-
played a strong eosinophil recruitment (79.07 6 1.99%,
1.66 6 0.32 3 106 eosinophils in the BALF as compared
with control PBS-aerosolized mice: 3.12 6 0.42%; 0.03 6
0.003 3 106). OVA-aerosolized mice were then randomly
assigned to PBS INT or OVA INT group at day 38 and treated
intranasally with OVA in a dose-escalating schedule (0.5, 1.0
and 1.5 mg) every day for 3 days from D38. Control mice re-
ceived PBS alone. One week after INT with OVA (D47), an en-
hanced inflammatory cell recruitment (total cell and eosinophil
count) was observed in BALF, which was inversely correlated
to the intranasal dose of OVA (Fig. 1A–C). On the contrary, af-
ter challenge with OVA aerosols (D57), inflammatory cell re-
cruitment was markedly impaired, however, without evidence
of a dose effect (Fig. 1D–F). These data clearly indicated that
INT with OVA was able to protect allergen re-exposed mice
from recruiting eosinophils and, to a lesser extent, lympho-
cytes into the bronchial lumen, both major players of airway
inflammation. Inhibition of eosinophil recruitment at D57 was
preceded by apparent activation of inflammation post-INT in
an inversely correlated dose response at D47.
To evaluate the duration of protection, the interval between
INT with OVA and re-exposure to OVA aerosols was
extended from 10 to 18 or 32 days. Longer time intervals
further attenuated BALF eosinophil recruitment (Fig. 2A).
Moreover, when aerosol challenges with OVA were repeated
twice at 30-day interval, eosinophil recruitment appeared to
be durably and strongly inhibited (Fig. 2B). Inhibition of
eosinophil recruitment into BALF was antigen specific since
INT with human albumin (HAS) in OVA-sensitized mice had
no effect on eosinophil recruitment into BALF upon OVA
aerosol challenge (Fig. 2C and D).
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OVA INT inhibits AHR, EPO production and cell proliferation
To determine whether inhibition of eosinophil influx into BALF
was also accompanied by a decrease in other parameters of
lung inflammation, AHR, EPO and lymphocytes proliferation
were assessed after re-exposure to OVA aerosols (D57). At this
time point, AHR and EPO activity significantly decreased in
OVA INT mice (Fig. 2E and F), whereas significantly higher
levels of EPO were detected at D47 (Fig. 2F). These data
suggested that INT with OVA not only inhibited eosinophil re-
cruitment into bronchial lumen but also in lung tissue itself. Fi-
nally, T-cell proliferation assays to OVA led to marked
allergen-specific T-cell hyporesponsiveness at D57 (Fig. 2G).
To further support this observation, CFSE-labelled OVA trans-
genic T cells from D011.10 mice were transferred into OVA
INT mice at D54. Tracked by cytofluorimetry at D57, they di-
vided less actively as compared with PBS INT mice (Fig. 2H).
OVA INT inhibits IgE production upon allergen re-exposure
and generates competitive anti-OVA IgG
After OVA challenge (D57), a strong production of
OVA-specific IgE was induced in control mice, whereas
IgE in OVA INT mice remained at baseline level in
contrast to OVA-specific IgG1 (Fig. 3A and B). IgG2a pro-
duction was similar in OVA- and PBS-treated mice (Fig.
3C). To evaluate a potential competition between OVA-spe-
cific IgG and IgE for binding sites, an anti-IgE capture
ELISA was performed as an alternative approach. In this
condition, we observed a strong IgE production in the OVA
INT group at D47, which remained constant after challenge
(D57) (Fig. 3D), indicating that the low IgE levels observed
after challenge in OVA INT mice resulted both from inhibi-
tion of IgE production and competition with specific
anti-OVA IgG.
Fig. 3. Regulation of OVA-specific IgE by OVA INT (1.5 mg). Sera were collected at D47 and D57. OVA-specific IgE (A), IgG1 (B) and IgG2a (C)
were quantified by ELISA. (D) OVA-specific IgE quantified by indirect method to avoid interactions with IgG. Dilutions of mouse serum were 1:20
for IgE, 1:500 000 for IgG1 and 1:1000 for IgG2a. *compared with PBS; #compared with D47. *P < 0.05; **P < 0.01; ***P < 0.001.
Fig. 4. OVA INT (1.5 mg) prevents cytokines production in lungs upon allergen challenge. Lungs were harvested at D47 (after INT) and D57
(after challenge). Cytokines were measured by ELISA in supernatants of lung homogenates. (A) IL-4, (B) IL-5, (C) IL-10, (D) TGFbeta, (E) IFNc. *P
< 0.05; **P < 0.01; ***P < 0.001.
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OVA INT prevents Th2 cytokine production upon re-exposure
to OVA
In supernatants of lung homogenates, IL-4, IL-5 and IL-10
production followed the same kinetics: a vigorous induction
after INT (D47) and a marked inhibition upon re-exposure to
OVA in OVA INT mice (D57) (Fig. 4A–C), in contrast to TGFb
strongly stimulated after OVA re-exposure (Fig. 4D). IFNc
production did not significantly differ between groups at
D47 and D57 (Fig. 4E). In the supernatants of BLN or lung
cells stimulated with OVA, IL-4, IL-5, IL-10, IL-13 and IFNc,
production did not significantly differ at D47 between OVA
INT mice and controls (Fig. 5A–E), except for IL-10, which
significantly increased in BLN cells of OVA INT mice (Fig.
5C). In contrast, 3 days after re-exposure to OVA, BLN and
lung cells of OVA INT mice produced significantly less IL-4,
IL-5, IL-10 and IL-13 than cells from controls. Production of
IFNc by BLN cells of OVA INT mice was also significantly
lower than in control animals. At this time point, IFNc was re-
petitively undetectable in lung cells. To further investigate
the potential role of IL-10 in the down-regulation of the im-
mune response, the frequency of CD4+ IL-10+ T cells was
also measured by flow cytometry. Following a profile similar
to IL-10 production in T-cell supernatants, INT with OVA was
associated with an enhanced frequency of CD4+ IL-10+
T cells at D47, whereas at D57 CD4+ IL-10+ T cells expan-
sion was markedly limited (Fig. 5F).
CD4+CD25 T cells protect recipient mice against OVA
challenge
To identify the key regulatory cell subsets, we first performed
a preliminary transfer experiment with total CD4+ T cells
from BLN and lung from OVA INT mice into OVA-sensitized
recipients. Transfer efficiently inhibited eosinophil recruitment
into the BALF of recipient asthmatic mice at D57 (Fig. 6A
and B). OVA-specific serum IgE as well as IL-4 and IL-10 in
lung supernatants were also down-regulated (Fig. 6C–E).
We next transferred CD4+CD25+ and CD4+CD25 cells
from OVA INT or PBS INT mice to OVA-sensitized mice.
CD4+CD25 T cells from OVA INT, but not from PBS INT,
mice protected recipient mice from recruiting eosinophil
into BALF upon allergen re-exposure. The transfer of
CD4+CD25+ T cells only partially suppressed BALF eosin-
ophilia (Fig. 6F). As measured by flow cytometry, the fre-
quency of CD4+CD25mTGFb+ T cells was significantly
enhanced in OVA INT mice at D57 (Fig. 6G) in contrast
to that of CD4+CD25+mTGFb+ T cells that did not differ
between groups (data not shown).
CD4+CD25mTGFb+ T cells play a key role in the induction of
tolerance
As suggested above (Fig. 6G), mTGFb+ subset of
CD4+CD25 T cells may play a role in the induction of toler-
ance upon INT with OVA in our model. To evaluate the role of
mTGFb-expressing CD4+CD25 T cells, CD4+CD25 T cells
were first purified from animals treated intranasally with
OVA then depleted by magnetic cell sorting from mTGFb-
expressing CD4+CD25 T cells. BALF from OVA-sensitized/
OVA aerosol-exposed animals transferred with mTGFb-
expressing CD4+CD25 T cells were significantly less
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Fig. 5. OVA INT (1.5 mg) prevents cytokines production by BLN and
lung cells 3 days after allergen challenge. BLN and lungs were
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inflammatory than BALF from animals transferred with
mTGFb-depleted CD4+CD25 T cells, as expressed by total
inflammatory cell number and eosinophil number (Fig. 6H).
This strongly indicated that CD4+CD25mTGFb+ T cells
played a key role in the induction of intranasal tolerance to
OVA. Nonetheless, the depletion of CD4+CD25mTGFb+
T cells only led to partial reversion of tolerance, suggesting
that mTGFb+-expressing CD4+CD25 T cells may not be the
sole partners involved in this phenomenon.
CD4+CD25+ T cells are necessary for the induction of
CD4+CD25 T cells with regulatory activity
As previously shown, the deletion of CD4+CD25+ T cells prior
to INT with OVA completely abrogated the induction of toler-
ance (24). To verify the hypothesis that CD4+CD25+ T cells
(>80% Foxp3+) were indispensable intermediates in the
mechanisms leading to the induction of CD4+CD25 T cells
with regulatory properties, OVA-sensitized mice were treated
with anti-CD25 mAb PC61 or with PBS as control at D31
prior to INT with OVA, then at D38 and D45 and finally re-
exposed to OVA aerosols (Fig. 7A). Mice were sacrificed at
D52 and CD4+CD25 T cells purified by magnetic cell
sorting. CD4+CD25 T cells from PC61 pre-treated or
control animals were then transferred to OVA-sensitized/OVA
aerosol challenged mice at D35. Transferred animals
were re-exposed to OVA aerosols and BALF analysed for
inflammatory cell count (Fig. 7B). There was no significant
difference between non-transferred control animals and
CD25-depleted/CD4+CD25 T cell-transferred animals. In
contrast, BALF from mice transferred with CD4+CD25
T cells from CD25 non-depleted animals were significantly
less inflammatory as measured by eosinophil count.
This strongly suggested that CD4+CD25+ T regulatory cells
were indispensable for induction of tolerance and required
for CD4+CD25 T cells education into cells with regulatory
properties.
Induction of tolerance via the nasal route also occurs in the
absence of IL-10 expression
To evaluate the role of IL-10 in the induction of tolerance,
we took advantage of the C57BL/10 IL-10/ knockout
model (Fig. 8). After sensitization with OVA and exposure to
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OVA aerosols, mice were treated intranasally either with OVA
or with PBS as described in Fig. 1. As demonstrated in the
BALB/c IL-10+/+ model, a marked down-regulation of total in-
flammatory cells and eosinophils in BALF was observed not
only in C56BL/10 IL-10+/+ mice (Fig. 8A and C) but also in
C56BL/10 IL-10/ mice (Fig. 8B and D) upon INT with OVA
and re-exposure to OVA aerosols at D57. There was no sig-
nificant difference in BALF infiltration between IL-10/ mice
and IL-10+/+ mice. This strongly suggested that IL-10 may
not play a unique role in the down-regulation of inflammatory
infiltrate in BALF in this model and especially in the down-
regulation of eosinophil recruitment.
Discussion
We demonstrated in this study the ability of nasal application
of OVA to protect against further re-exposure to OVA aero-
sols in a therapeutic model of asthma. Mucosal delivery of
OVA via the nasal route markedly reduced eosinophil
and other inflammatory cell recruitment into BALF and bron-
chial airways, as well as AHR, in an antigen-specific manner.
Th2 and Th1 cytokines were strongly inhibited, and OVA-
specific T cell proliferative response was markedly de-
creased, establishing a state of tolerance to OVA. Protection
upon re-exposure to OVA was sustained up to 32 days
after nasal application of allergen. Moreover, tolerance to
allergen re-exposure could be transferred by CD4+CD25
T cells from tolerized mice. In vivo, in the absence of
CD4+CD25+(Foxp3+) T cells, CD4+CD25 T cells from toler-
ized mice were in contrast unable to acquire regulatory
properties and to transfer tolerance. A significant fraction of
tolerogenic CD4+CD25 T cells expressed mTGFb, which
appeared to play a significant role in the induction of toler-
ance in contrast to IL-10.
Taken together, our data supported a down-regulation of
both Th1 and Th2 cytokines rather than a strict Th2 to Th1
shift, an effect compatible with observations done in models
of allergen SIT (30, 31) and in venom immunotherapy (32).
These results also demonstrated the potential of mucosal
delivery of allergen to efficiently down-regulate an estab-
lished bronchial inflammation and to improve asthma. In
this regard, our observations are in line with a previously
published model demonstrating the superior capacity of in-
tranasal immunotherapy over intradermal immunotherapy in
down-regulating airway allergic inflammation (13). However,
in contrast to our approach, Takabayashi et al. were not able
to down-regulate Th2 inflammation at a systemic level. The
higher doses of OVA used in our model may account for this
difference. Furthermore, in our approach, INT with OVA was
not only able to induce long-term protection (Fig. 2) but also
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resistance to a second series of allergen challenges. This
sustained effect of INT with OVA strongly suggested that
a long-term suppressive memory response was taking
place, in agreement with the long-term protection provided
by subcutaneous immunotherapy in mouse (33) and in
human (8).
INT with OVA abrogated the rise in OVA-specific IgE pres-
ent in control mice after re-exposure, whereas in contrast
IgG1 increased. Similarly, after intranasal but not oral toler-
ance in a prophylactic murine model of asthma, Th2 cytokine
secretion by allergen-specific T cells were down-regulated
although IgG1 increased concomitantly (34).These findings
were globally in agreement with allergen SIT to respiratory
or hymenoptera allergens in human, associated with an
increase in serum allergen-specific IgG1, IgG4 and IgA (5,
35, 36). In vitro, mouse IgG1 were able to block human IgE
interaction with allergen by competing on similar Bet v 1
epitopes (37). IgG1 may thus take part to the protection
observed in OVA INT animals upon re-exposure to allergen.
At D47, i.e. 1 week after OVA INT, we observed a marked
enhancement of the inflammatory response in lungs and
BLN, in particular of the Th2 cytokine response (Figs 4
and 5). Eosinophil recruitment into BALF was strongly stimu-
lated with the lowest dose of OVA (0.5 mg) as compared
with the highest dose (1.5 mg) (Fig. 1), although both treat-
ment levels led to significant and comparable impairment
in eosinophil recruitment upon OVA aerosol challenges at
D57. These results are reminiscent of previous mice and hu-
man immunotherapy studies demonstrating that prior to tol-
erance induction, a transient inflammatory phase may
occur (12, 36, 38). Lung inflammation and T-cell activation in
the early phase of nasal allergen SIT appears therefore
a pre-requisite to immune response down-regulation.
The mechanisms underlying the down-regulation of the
allergic airway response in our model still need to be fully
characterized, but at that stage, our data suggest a role for
both CD4+CD25+ and CD4+CD25 T cells. Indeed, transfer
of CD4+ T cells from OVA INT mice reproduced the effect of
INT with OVA (Fig. 6). Moreover, protective effects were fully
reproduced by the transfer of CD4+CD25 T cells and only
when isolated from mice treated intranasally with OVA. This
strongly suggested that nasal application of OVA was able
to induce a subset of CD4+ T cells able to transfer tolerance,
i.e. to express regulatory properties. Our observations are
reminiscent of previous reports in models of autoimmunity,
where the in vivo transfer of CD4+CD25 T cells was able to
induce protection (39–41). However, this does not exclude
a role for CD4+CD25+ T cells as recently demonstrated
(21, 23). Importantly, although we were not able to dir-
ectly transfer tolerance with CD4+CD25+ T cells (>80%
Foxp3+) (24), we showed here that in the absence of
CD4+CD25+Foxp3+ T cells, CD4+CD25 T cells (>95%
Foxp3) were unable to acquire regulatory properties
(Fig. 7). How CD4+CD25+Foxp3+ natural T regulatory cells
exert their ‘educative’ action on induced CD4+CD25
Foxp3 T regulatory cells is still unclear. Our data support
a potential role for TGFb, a key regulatory cytokine involved
in the protection upon re-exposure to allergen (42, 43). This
was strongly suggested by the markedly enhanced produc-
tion of TGFb in lung supernatants ex vivo (Fig. 4D), although
we cannot rule out that part of this TGFb secretion may also
be due to non-immune cells (44). Furthermore, we know
from our previous publication that CD4+CD25+Foxp3+ T cells
express high level of mTGFb, suggesting a role for mTGFb
in the induction of CD4+CD25 with regulatory properties
(24). This interpretation has been previously supported by
a model of aerosolized antigen-induced tolerance involving
cell–cell contact with regulatory CD4+ T cells that co-express
mTGFb and Foxp3 (20). A synergy between mTGFb and
Cytotoxic T-Lymphocyte Antigen 4 in T regulatory cells-
mediated suppression of proliferation of CD25 effector
T cells has been previously demonstrated (45). Furthermore,
INT with OVA is associated with a significant enhancement
of the expression of mTGFb on CD4+CD25 T cells (Fig. 6).
Again, mTGFb appears to play here also a key role since the
exclusion by magnetic cell sorting of CD4+CD25mTGFb+
T cells from CD4+CD25 T cells transferred to asthmatic
recipients significantly enhanced eosinophil recruitment
into BALF. Exclusion of mTGFb cells, however, did not fully
restore lung inflammation suggesting the contribution of
other anti-inflammatory mechanisms. In this respect, the
question is still open whether the induction of CD4+CD25
tolerogenic T cells we observed (induced T regulatory cells)
may be further converted into CD4+CD25+Foxp3+ T cells
(42).
The anti-inflammatory role of IL-10 is in contrast debatable
in our model. Indeed, IL-10 production in lung homogenates
or in supernatants from BLN and lung cell culture rose
markedly after INT with OVA but sharply dropped after
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Fig. 8. Induction of tolerance in IL-10/ mice. C57BL/10 (wild type)
(A and B) and C57BL/10 IL-10/ (C and D) mice were sensitized to
OVA as described in Fig. 1, namely with two i.p. injections of 10 lg
alum-adsorbed OVA and three 0.25% OVA aerosols. Ten days later,
mice were intranasally treated with 1.5 mg OVA or PBS for controls
and challenged three times with OVA 0.25% aerosols at days 50, 52
and 54. BALF were harvested at day 57. (A and C) Total cell in BALF
expressed as cell number. (B and D) Mononuclear cell subpopula-
tions in BALF expressed as cell number. ***P < 0.001.
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re-exposure to OVA aerosols (Fig. 5). These findings corre-
lated with an increased frequency of CD4+ IL-10+ T cells in
lungs and BLN after INT with OVA contrasting with a marked
decrease after OVA challenges. Our data may possibly be
representative of IL-10 production by T regulatory cells as
suggested in prophylactic models (16, 19) but may also re-
sult from IL-10 production by OVA-specific Th2 effector cells
(46). Furthermore, tolerance induction to OVA was obtained
in IL-10/ mice, although in a different genetic background,
showing that IL-10 was not unique in the process leading to
tolerance. These data were in agreement with our previous
observations indicating that the frequency of CD4+CD25IL-
10+ T cells from tolerized mice was low (as compared with
CD4+CD25+ T cells) and did not significantly differ from the
frequency of CD4+CD25IL-10+ T cells in non-tolerized
animals (24). We cannot, however, fully exclude a possibly
redundant anti-inflammatory role for IL-10 or an activity on
other parameters than those considered here (lung eosino-
philia, IgE production). We indeed showed an enhanced
production of IL-17 in the lungs of tolerized animals (24),
a result that may suggest a regulatory contribution of this
cytokine in turning down the Th2 immune response of asth-
matic mice in the absence of concomitant enhancement of
the Th1 response (47). On the one hand, IL-17 induction in
tolerized mice may support an immunoregulatory activity of
IL-17 in dampening the Th2 airways inflammation (47–49).
On the other hand, IL-17 secretion into the lungs would be
a logical consequence of the concomitant action of TGFb
and IL-6 leading to the generation of Th17 cells (50). A bet-
ter understanding of the IL-17 response and involvement in
tolerance induction is ongoing in our laboratory.
Taken together, our model of tolerance in asthma contrib-
uted to demonstrate that INT with OVA led to the induction
of CD4+CD25 T cells with regulatory properties under the
control of CD4+CD25+Foxp3+ T cells. The fine mechanisms
leading to the generation of T regulatory cells appeared to
involve mainly TGFb/mTGFb expression as key players, the
respective roles of which will have to be further analysed.
This model also strongly supports allergen-specific induction
of tolerance based on a mucosal approach in human with
allergic asthma.
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